Assessment of TPS tumor marker with ELISA for early detection and monitoring of Breast Cancer

Fatal disease of cancer, ranks second after cardiovascular disease, as the most important causes of mortality in many developing countries, including Iran. Breast cancer is the most common disease among women. TPS is one of the tumor markers which has specially been considered due to its exclusive physiological characteristics like its easy measurement in serum of cancer patients. This study has been set up to evaluate the efficiency of this tumor marker in the prognosis, treatment control and follow up of patients with Breast cancer. TPS has been measured with ELISA in 34 persons including 28 healthy people and 6 patients with breast cancer. Sampling has been done in three times depending on treatment methods. TPS has been measured in samples which contend of 2 to 3 ml of serum from patients and the health. The results has revealed that the serum TPS is not only as a measure of prognosis but also would be helpful in follow up and treatment control of the disease. Serological analysis can be settled in the diagnosis and trend of cancer with production of polyclonal antibody against TPS gene family and planning appropriate pattern.